The controversial results of KEYNOTE-028 and KEYNOTE-158, which despite the PD-L1 expression in tumor cells, the objective response rate was higher in PD-L1-negative tumors, indicate that the tumor microenvironment is crucial for the PD-1/PD-L1 pathway for VSCCs [37,42]. The gene discussed is PDCD1; the disease is neoplasm.